BRPI0519495A2 - composto ou um sal farmaceuticamente aceitÁvel do mesmo, uso de um composto, e, mÉtodo para preparar um composto - Google Patents

composto ou um sal farmaceuticamente aceitÁvel do mesmo, uso de um composto, e, mÉtodo para preparar um composto

Info

Publication number
BRPI0519495A2
BRPI0519495A2 BRPI0519495-4A BRPI0519495A BRPI0519495A2 BR PI0519495 A2 BRPI0519495 A2 BR PI0519495A2 BR PI0519495 A BRPI0519495 A BR PI0519495A BR PI0519495 A2 BRPI0519495 A2 BR PI0519495A2
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutically acceptable
acceptable salt
compounds
Prior art date
Application number
BRPI0519495-4A
Other languages
English (en)
Inventor
Edmund Idris Graziani
Kevin Pong
Jerauld Skotnicki
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0519495A2 publication Critical patent/BRPI0519495A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITÁVEL DO MESMO, USO DE UM COMPOSTO, E, MÉTODO PARA PREPARAR UM COMPOSTO. A presente invenção fornece compostos da seguinte estrutura, em que R~ 1~, R~ 2~, R~ 6~, R~ 7~ e R~ 15~ são definidos aqui definidos. Estes compostos são usados no tratamento de distúrbios ou complicações neurológicas em virtude de derrame ou lesão da cabeça, doença neoplásica benigna ou maligna, carcinomas e adenocarcinomas, distúrbios proliferativos e distúrbios inflamatórios. Os compostos são desta forma usados como agentes neuroprotetores, antiproliferativos e antiinflamatórios.
BRPI0519495-4A 2004-12-20 2005-12-15 composto ou um sal farmaceuticamente aceitÁvel do mesmo, uso de um composto, e, mÉtodo para preparar um composto BRPI0519495A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63766604P 2004-12-20 2004-12-20
PCT/US2005/045551 WO2006068932A2 (en) 2004-12-20 2005-12-15 Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders

Publications (1)

Publication Number Publication Date
BRPI0519495A2 true BRPI0519495A2 (pt) 2009-02-03

Family

ID=36087657

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519495-4A BRPI0519495A2 (pt) 2004-12-20 2005-12-15 composto ou um sal farmaceuticamente aceitÁvel do mesmo, uso de um composto, e, mÉtodo para preparar um composto

Country Status (26)

Country Link
US (5) US7276498B2 (pt)
EP (1) EP1828202B1 (pt)
JP (1) JP5094406B2 (pt)
KR (1) KR20070090913A (pt)
CN (1) CN101084227B (pt)
AR (1) AR052269A1 (pt)
AT (1) ATE549342T1 (pt)
AU (1) AU2005319454B2 (pt)
BR (1) BRPI0519495A2 (pt)
CA (1) CA2590155A1 (pt)
CR (1) CR9148A (pt)
DK (1) DK1828202T3 (pt)
ES (1) ES2380779T3 (pt)
GT (1) GT200500368A (pt)
HN (1) HN2005035605A (pt)
IL (1) IL183664A (pt)
MX (1) MX2007007408A (pt)
NI (1) NI200700157A (pt)
NO (1) NO20072664L (pt)
NZ (1) NZ574663A (pt)
PE (1) PE20060765A1 (pt)
RU (1) RU2394036C2 (pt)
SG (1) SG158143A1 (pt)
TW (1) TW200628152A (pt)
UA (1) UA94034C2 (pt)
WO (1) WO2006068932A2 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537829A (en) 2002-07-30 2006-09-29 Wyeth Corp Parenteral formulations containing a rapamycin hydroxyester
EP1720886A1 (en) * 2004-03-02 2006-11-15 Wyeth Macrolides and methods for producing same
MXPA06014080A (es) * 2004-06-03 2007-02-15 Wyeth Corp Agregado de genes biosinteticos para la produccion de un policetido complejo.
AU2005319454B2 (en) * 2004-12-20 2012-08-09 Wyeth Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
CA2590254A1 (en) * 2004-12-20 2006-06-29 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
BRPI0619592A2 (pt) * 2005-12-07 2016-09-06 Wyeth Corp métodos para medir a qualidade da partícula de um composto de rapamicina, para determinar o tamanho de partícula médio de uma amostra e a cristalinidade de um composto de rapamicina, e para a purificação de rapamicina
US7622578B2 (en) * 2005-12-07 2009-11-24 Wyeth Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate
AR058282A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
RU2008132779A (ru) 2006-03-07 2010-04-20 Вайет (Us) Аналоги меридамицина для лечения нейродегенеративных заболеваний
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20100196355A1 (en) * 2007-01-29 2010-08-05 Wyeth Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
WO2009100214A2 (en) * 2008-02-05 2009-08-13 The Johns Hopkins University Induction of thyroid iodide-handling gene expression in human cancers
US20090209527A1 (en) * 2008-02-19 2009-08-20 Wyeth Methods for Using Rapamycin Analogues in the Treatment of Neurological Disorders
EP2365802B1 (en) 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules of rapamycin and use for treating cancer
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
AU2010233073B2 (en) 2009-04-10 2014-07-31 Haiyan Qi Novel anti-aging agents and methods to identify them
US20170079962A1 (en) 2009-11-11 2017-03-23 Rapamycin Holdings, Llc Oral Rapamycin Preparation and Use for Stomatitus
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CA2794196A1 (en) 2010-03-23 2011-09-29 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
ES2372077B2 (es) * 2010-06-24 2012-05-18 Universidad De Sevilla Uso de la rapamicina para el tratamiento de los déficits cognitivos asociados al s�?ndrome de down.
EP2446886A1 (en) * 2010-10-29 2012-05-02 Fondazione Telethon Autophagy regulators and the uses thereof in the treatment of collagen VI defective Muscular Dystrophies
SG10201600912SA (en) 2011-03-04 2016-03-30 Intrexon Corp Vectors conditionally expressing protein
EP2589383A1 (en) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
US20150290176A1 (en) 2012-10-12 2015-10-15 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
ITMI20122065A1 (it) * 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
EP2968281B1 (en) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor inhibitors for prevention of intestinal polyp growth
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
GB2538747B (en) * 2015-05-27 2022-04-13 Airbus Operations Ltd A measuring apparatus for measuring properties of a surface
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
UY37343A (es) 2016-07-25 2018-02-28 Intrexon Corp Control del fenotipo en plantas
CN110139933B (zh) 2016-11-09 2024-03-08 英特瑞克斯顿股份有限公司 共济蛋白表达构建体
EP3848065B1 (en) 2017-05-15 2023-07-26 C. R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
EP3880266B1 (en) 2018-11-14 2025-05-07 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
EP3914245A4 (en) * 2019-01-22 2022-08-24 Aeovian Pharmaceuticals, Inc. MTORC-1 MODULATORS AND USES THEREOF
WO2020209828A1 (en) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
EP4185590A2 (en) * 2020-07-21 2023-05-31 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof
CN114306330A (zh) * 2022-01-27 2022-04-12 中以海德人工智能药物研发股份有限公司 雷帕霉素在治疗或预防乙型肝炎中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
DE1545824A1 (de) 1965-06-21 1969-12-11 Bayer Ag Verfahren zur Herstellung von 2-Sulfonamido- bzw. 2-Sulfonhydrazido-Benzoxazinonen
GB1325047A (en) 1969-08-11 1973-08-01 Ciba Geigy Ag Rifamycin compounds and processes for their manufacture
US3686238A (en) 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3900465A (en) 1973-04-05 1975-08-19 Lepetit Spa 3-formylrifamycin azines
US3905981A (en) 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US4127720A (en) 1977-09-21 1978-11-28 Bristol-Myers Company Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity
JPH0262875A (ja) 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
JPH05507915A (ja) 1990-06-11 1993-11-11 藤沢薬品工業株式会社 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
DE4021404A1 (de) 1990-07-05 1992-01-09 Sandoz Ag Heteroatome enthaltende trycyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
GB2249027A (en) 1990-10-23 1992-04-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for hepatic failure
WO1992013862A1 (en) 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Lactone compounds
US5604294A (en) 1991-09-05 1997-02-18 Luly; Jay R. Macrocyclic immunomodulators
ES2179823T3 (es) 1991-09-05 2003-02-01 Abbott Lab Inmunosupresor macrolido.
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
DE69435044T2 (de) 1993-04-23 2008-09-18 Wyeth Rapamycin - Konjugate und Antikörper
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5525610A (en) 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
EP0833828B1 (en) * 1995-06-09 2002-11-20 Novartis AG Rapamycin derivatives
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5717092A (en) 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US6187784B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
AU761083B2 (en) 1998-06-03 2003-05-29 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6015809A (en) 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
BR9913052A (pt) 1998-08-17 2001-05-08 American Home Prod Rapamicinas fotocilizadas
AU2478500A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU7124000A (en) 1999-09-09 2001-04-10 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6569867B2 (en) 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
WO2001034816A1 (en) 1999-10-29 2001-05-17 Kosan Biosciences, Inc. Rapamycin analogs
EP1282626A2 (en) 2000-05-17 2003-02-12 Kosan Biosciences, Inc. Polyketide derivatives
MXPA04001523A (es) 2001-08-22 2004-05-31 Wyeth Corp Dialdehidos de rapamicina.
BR0211986A (pt) 2001-08-22 2004-09-28 Wyeth Corp 29-enóis de rapamicina
CA2492153C (en) 2002-07-16 2012-05-08 Biotica Technology Limited Production of polyketide fkbp-ligand analogues
DE102004049700B4 (de) 2004-10-12 2007-10-18 Aircabin Gmbh Kraftunterstützungsvorrichtung mit lastabhängiger Kraftunterstützung
AU2005319454B2 (en) 2004-12-20 2012-08-09 Wyeth Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
CA2590254A1 (en) * 2004-12-20 2006-06-29 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
RU2008132779A (ru) 2006-03-07 2010-04-20 Вайет (Us) Аналоги меридамицина для лечения нейродегенеративных заболеваний

Also Published As

Publication number Publication date
HN2005035605A (es) 2010-08-05
TW200628152A (en) 2006-08-16
DK1828202T3 (da) 2012-05-07
IL183664A0 (en) 2007-09-20
ES2380779T3 (es) 2012-05-18
JP5094406B2 (ja) 2012-12-12
NZ574663A (en) 2010-05-28
US20090239855A1 (en) 2009-09-24
EP1828202A2 (en) 2007-09-05
GT200500368A (es) 2006-07-13
US7470682B2 (en) 2008-12-30
SG158143A1 (en) 2010-01-29
US7795252B2 (en) 2010-09-14
US7276498B2 (en) 2007-10-02
ATE549342T1 (de) 2012-03-15
AU2005319454A1 (en) 2006-06-29
PE20060765A1 (es) 2006-10-02
US20090203682A1 (en) 2009-08-13
US20060135549A1 (en) 2006-06-22
AR052269A1 (es) 2007-03-07
RU2394036C2 (ru) 2010-07-10
KR20070090913A (ko) 2007-09-06
JP2008524240A (ja) 2008-07-10
CA2590155A1 (en) 2006-06-29
EP1828202B1 (en) 2012-03-14
HK1108442A1 (en) 2008-05-09
NO20072664L (no) 2007-06-25
IL183664A (en) 2012-06-28
WO2006068932A2 (en) 2006-06-29
WO2006068932A3 (en) 2006-10-19
RU2007119584A (ru) 2009-01-27
NI200700157A (es) 2008-04-21
AU2005319454B2 (en) 2012-08-09
CN101084227B (zh) 2011-11-16
MX2007007408A (es) 2007-07-12
US20070142423A1 (en) 2007-06-21
CR9148A (es) 2007-11-23
US20080004264A1 (en) 2008-01-03
US7560457B2 (en) 2009-07-14
CN101084227A (zh) 2007-12-05
UA94034C2 (ru) 2011-04-11

Similar Documents

Publication Publication Date Title
BRPI0519495A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, uso de um composto, e, mÉtodo para preparar um composto
SV2002000357A (es) Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo ref pc10748amag/bb
BRPI0411699A (pt) compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
BRPI0412893A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto
DOP2003000639A (es) Pirazolopiridinas substituidas con carbamato
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
GT200000037A (es) Procedimientos e intermedios para preparar compuestos anticancerosos.
BRPI0519593A2 (pt) composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto
BR0213734A (pt) Derivados de carboxamida heteroaromático para o tratamento de inflamação
BRPI0312398B8 (pt) derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído
EA200702387A1 (ru) Имидазохинолины в качестве ингибиторов липидкиназы
BR0113776A (pt) Composição de pirrolocarbazóis selecionados fundidos e método para tratar e prevenir várias doenças usando a citada composição
HN1999000124A (es) Derivados de pirazol substituido.
ATE397458T1 (de) Neue heilmittel für krebs
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO2009067397A3 (en) Treatment for solid tumors
AR021912A1 (es) Uso de apomorfina para el tratamiento de la disfuncion erectil organica en varones
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
BR0208405A (pt) Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
BR9808263A (pt) Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto.
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
DK1355626T3 (da) Veterinær, dermatologisk sammensætning

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.